Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Englisch, C; Konigsbrugge, O; Nopp, S; Moik, F; Quehenberger, P; Preusser, M; Pabinger, I; Ay, C.
Antithrombin Activity and Association with Risk of Thrombosis and Mortality in Patients with Cancer
INT J MOL SCI. 2022; 23(24): 15770 Doi: 10.3390/ijms232415770 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Co-Autor*innen der Med Uni Graz

Moik Florian

Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:

Venous and arterial thromboembolism (VTE/ATE) are common complications in cancer patients. Antithrombin deficiency is a risk factor for thrombosis in the general population, but its connection to risk of cancer-associated thrombosis is unclear. We investigated the association of antithrombin activity levels with risk of cancer-associated VTE/ATE and all-cause mortality in an observational cohort study including patients with cancer, the Vienna Cancer and Thrombosis Study. In total, 1127 patients were included (45% female, median age: 62 years). Amongst these subjects, 110 (9.7%) patients were diagnosed with VTE, 32 (2.8%) with ATE, and 563 (49.9%) died. Antithrombin was not associated with a risk of VTE (subdistribution hazard ratio (SHR): 1.00 per 1% increase in antithrombin level; 95% CI: 0.99-1.01) or ATE (SHR: 1.00; 95% CI: 0.98-1.03). However, antithrombin showed a u-shaped association with the risk of all-cause death, i.e., patients with very low but also very high levels had poorer overall survival. In the subgroup of patients with brain tumors, higher antithrombin levels were associated with ATE risk (SHR: 1.02 per 1% increase; 95% CI: 1.00-1.04) and mortality (HR: 1.01 per 1% increase; 95% CI: 1.00-1.02). Both high and low antithrombin activity was associated with the risk of death. However, no association with cancer-associated VTE and ATE across all cancer types was found, with the exception of in brain tumors.

Find related publications in this database (Keywords)

antithrombin

antithrombin deficiency

cancer-associated thrombosis

© Med Uni Graz • Impressum